Zydus receives final approval from USFDA for Donepezil Hydrochloride Tablets

01 Sep 2017 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Donepezil Hydrochloride Tablets, in the strength of 23 mg. The drug is indicated for the treatment of dementia of the Alzheimer’s disease.

The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 140 approvals and has so far filed over 300 AND As since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.


Zydus Lifesciences Share Price

922.05 0.80 (0.09%)
16-Dec-2025 11:46 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1788.20
Dr. Reddys Lab 1275.00
Cipla 1506.60
Zydus Lifesciences 922.05
Lupin 2091.20
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×